Hemab Therapeutics

As we recognize #BleedingDisordersAwarenessMonth, every story shared fuels our commitment to innovation. We’re incredibly grateful for the collaboration and trust from those living with bleeding disorders. Your experiences inspire us to drive life-changing medicines forward. As our CEO Benny Sorensen says, "The moment is NOW to catapult treatments into the 21st century for those neglected for decades."

March is #BleedingDisordersAwarenessMonth, a time to shed light on the daily challenges, limited treatment options, and unmet needs of those living with bleeding disorders. Too many face uncertainty in their day-to-day lives, complications, and a lack of effective care. At Hemab, we’re committed to changing that. We are dedicated to developing breakthrough therapies for underserved bleeding disorders, ensuring every impacted person has access to the care they need. Throughout the month, we’ll share perspectives from those living with bleeding disorders and community members who are driving progress in this space. Follow along to hear these stories and help raise awareness.

Today we recognize Glanzmann Thrombasthenia (GT) Awareness Day. Living with GT means facing the daily challenge of a life-threatening bleeding disorder that affects the body’s ability to form blood clots, making even minor injuries potentially catastrophic. The impact on individuals and families is profound, both physically and emotionally. For over 100 years, there has been little progress in effective treatments for GT, leaving those affected without viable options. At Hemab, we’re committed to breaking this cycle of stagnation. We are advancing research and developing therapies that aim to improve the lives of those living with GT and other rare bleeding disorders. Our focus is placed on developing innovative solutions that can offer real hope for the future. Learn more about how we are advancing the first prophylactic treatment for GT at https://hemab.com/ Stay tuned this month as we continue to share our mission and raise awareness in honor of #BleedingDisordersAwarenessMonth. Together, we can amplify hope and support for the bleeding disorders community. #GlanzmannThrombastheniaAwarenessDay

The first participant with Glanzmann thrombasthenia (GT) to receive HMB-001 took a giant leap forward. Their commitment to clinical research is advancing our understanding of GT. Since then, many more participants have enrolled in the Phase 2 study of HMB-001, fueling momentum in GT. At #EAHAD2025, the momentum across the field of bleeding disorders was unmistakable. New therapies are expanding options for people with GT, Von Willebrand Disease, and other rare conditions. With combination treatments on the horizon, the future of care is becoming more tailored and precise. On #RareDiseaseDay, we celebrate the progress made and the continued drive to improve care for those living with rare bleeding disorders.

Today on #RareDiseaseDay, we celebrate a recent significant milestone: the first participant to receive HMB-002, our investigational treatment for Von Willebrand Disease. Their courage to step forward and get involved advances research towards better treatment options and also helps shape the future for the next generation. We are deeply grateful to the participants, investigators, and clinical researchers dedicated to reimagining what’s possible. We captured Dr. Suthesh Sivapalaratnam’s anticipation of this milestone just a day before the first dose in the Velora Pioneer study. The future of bleeding disorders is being written today.

This #RareDiseaseDay, we recognize the strength and resilience of the 300 million people worldwide living with a rare disease. While the journey can feel isolating, the global rare disease community is united in the pursuit of better care, breakthrough treatments, and a future where no one is left behind. For people with bleeding disorders like Glanzmann thrombasthenia, Von Willebrand Disease, Factor VII Deficiency, and other clotting and bleeding conditions, the absence of effective preventative treatments can make even a small injury life-threatening. The lack of options underscores the tremendous impact these disorders have on daily life, and the urgent need for a solution. At Hemab, we’re not just developing treatments—we’re amplifying the voices of those impacted, championing progress, and driving change. By reimagining the standard of care for underserved bleeding and thrombotic disorders, we’re shaping a future where prevention and functional cures become reality. Learn more at https://hemab.com/

Hemab is thrilled to announce that the first participant has been dosed in our Phase 1/2 clinical trial with HMB-002. This marks a significant step forward in bringing much-needed treatment options to the Von Willebrand Disease (VWD) community, one that has long been underserved and overlooked. A huge thank you to the people living with VWD, investigators, and teams making this possible. Stay tuned as we continue to progress transformative, preventative treatments for people living with rare bleeding and thrombotic disorders. Read more: https://lnkd.in/ew4Uv8QT

Hemab is thrilled to join #GTH2025 in Lausanne, Switzerland, where innovation in thrombosis and haemostasis meets real-world impact. Gesellschaft für Thrombose- und Hämostaseforschung e.V., GTH's event allows us to collaborate with leading experts, share insights on HMB-001 and HMB-002, and advance our mission to pioneer the first prophylactic treatments and functional cures for genetically driven bleeding and thrombotic disorders. At the core of our work is a deep commitment to patients urgently awaiting better treatment options. Together, we aim to spark transformative discussions, build impactful partnerships, and bring hope to those who need it most.

ICYMI: Last week at the annual European Association for Haemophilia and Allied Disorders (EAHAD) congress, we presented interim data from the ongoing Phase 2 study of HMB-001 for Glanzmann thrombasthenia and HMB-002 preclinical data for Von Willebrand Disease. These studies wouldn’t have been possible without the invaluable contributions of Principal Investigators Laurent Frenzel, MD, PhD, and Suthesh Sivapalaratnam, MD, PhD. Their commitment to advancing treatment in the bleeding disorders community is driving real progress for patients. Together, we are reimagining the standard of care for patients everywhere. Learn more about our presentations at #EAHAD2025: https://lnkd.in/etiAu6bS

NEWS: Today at #EAHAD2025, we presented interim data from the ongoing Phase 2 study of HMB-001, designed to be the first ever prophylactic treatment for Glanzmann thrombasthenia, as well as promising HMB-002 preclinical data for Von Willebrand Disease. HIGHLIGHTS: • Interim results demonstrate treatment with HMB-001 resulted in >50% reduction in treated bleeds at all tested dose levels • HMB-002 data demonstrate a promising safety and efficacy profile with high-affinity target-selective binding and preservation of key physiological functions of Von Willebrand Factor when HMB-002 is bound Learn more about our progress in pioneering first-in-class prophylactic treatments for rare bleeding disorders: https://lnkd.in/etiAu6bS